Will Anti-TIGITs Prove Their Value in 2023?
The promise of TIGIT as an oncology target in combination with PD-1/PD-L1 inhibitors has prompted an influx of investment into anti-TIGIT agents and five agents are already in advanced clinical trials. That initial enthusiasm has been dampened as of late, after disappointing Phase III data. Investors are hoping that 2023 will be the year that restores hope in the anti-TIGIT pipeline.
You may also be interested in...
Once heralded with optimism, the class of anti-TIGIT molecules has since fallen out of favor, plagued by a succession of disappointing findings.
Biopharma executives in Israel rely on their global footprint and a 'culture of resilience'.
Despite initial underwhelming competitive data on the cancer target, Merck said it is expanding its investment behind its anti-TIGIT drug vibostolimab. Roche updated investors on its program too.